The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for February 2018 (PDF).
This issue advises clinicians that mycophenolate mofetil or mycophenolic acid have teratogenic and genotoxic effects and while the current evidence does not indicate an increased risk of malformations or miscarriage in pregnancies while fathers were taking these medicines but is insufficient to rule out a risk. As a precaution it is recommended that men taking these drugs, or their female partner, should use effective contraception.
This issue also contains a summary of recent drug and device alerts, including a potential defect with midazolam (Buccolam®) oral syringed as reported last month, notification that a shortage of UK zanamivir (Relenza®) will be filled by stock from abroad and a warning that all Philips HeartStart MRx monitors/defibrillators will be affected by a significant delay in the fulfilment of orders for new batteries.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.